Abstract
Impaired cutaneous healing, leading to chronic wounds,
affects between 2 and 6% of the total population in most developed countries
and it places a substantial burden on healthcare budgets. Current treatments
involving antibiotic dressings and mechanical debridement are often not
effective, causing severe pain, emotional distress and social isolation in
patients for years or even decades, ultimately resulting in limb amputation.
Alternatively, gene therapy (such as mRNA therapies) emerges as a viable option
to promote wound healing through modulation of gene expression. However, protecting
the genetic cargo from degradation and efficient transfection into primary
cells remain significant challenges in the push to clinical translation.
Another limiting aspect of current therapies is the lack of sustained release
of drugs to match the therapeutic window. Herein, we have developed an
injectable, biodegradable and biocompatible hydrogel-based wound dressing that
delivers pBAE nanoparticles in a sustained manner over a range of therapeutic
windows. We also demonstrate that pBAE nanoparticles, successfully used in
previous in vivo studies, protect the mRNA load and efficiently
transfect human dermal fibroblasts upon sustained release from the hydrogel
wound dressing. This prototype wound dressing technology can enable the
development of novel gene therapies for the treatment of chronic wounds.
Supplementary materials
Title
Supporting Information
Description
Actions